TDAC · Translational Development Acquisition Corp.
$10.85
-0.01 (-0.09%)
At close · Sep 18
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In connection with the Company's assessment of going concern considerations in accordance with ASC 205-40, "Presentation of Financial Statements-Going Concern," management has determined that the liquidity issues and mandatory liquidation and subsequent dissolution, should the Company be unable to complete a Business Combination by the end of the Completion Window, raise substantial doubt about the Company's ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 24, 2027. The Company's plan to deal with the uncertainty is to complete a Business Combination prior to June 24, 2027 and to receive working capital from its Sponsor. There is no assurance that the Company's plans to consummate a Business Combination or to receive working capital from the Sponsor will be successful.”View the 10-Q filed Aug 14, 2026
Market Cap
$209.50M
Shares
19.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.85
Open$10.86
Day$10.84–10.88
52W close$10.34–10.90
Avg vol 30d33K
Short int19K · 0.1% float · 1.7d
Short vol9%
DataFeb 2025–Sep 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$5.54M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
37.9
Trailing earnings · reciprocal yield 2.6%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$85,877
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+4.9%
Trailing year
Short interest
0.1%
Latest settlement · 1.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very Low
Market backdrop
VIX 14.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
+0%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
91%
near high
Momentum
relative strength
1-month return
0%
trailing
6-month return
+3%
trailing
YTD return
+3%
this year
Relative strength
−17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
-11% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.10% of float · ▼ -48.1% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
48 holders — mid 1-yr range
Squeeze score
44
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
3%
annualized · 1-yr
Max drawdown
−1%
past year
ATR
0.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
91%
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
-11% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.10% of float · ▼ -48.1% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
48 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $10
Now $11 · 91%
Range high $11
vs 200-day avg +2%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TDAC
this stock
Translational Development Acquisition Corp.
|
$209.50M | +3.4% | — | — | 0.1% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
CCXI
Churchill Capital Corp XI
|
$684.55M | — | — | — | 6.7% |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$647.19M | +2.7% | — | — | 0.2% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$602.01M | +2.7% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TDAC | -0.1% | +0.1% | +3.1% | +0.0% | +3.4% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | +0.3% | +0.2% | -17.0% | +0.7% | -8.3% |